Does eplerenone have a future in the management of hypertension in Europe?

Journal of Human Hypertension

Volumn 20, Issue 11, 2006, Pages 829-832

  Gosse, P ^a   Macfadyen, R J ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BISPHOSPHONIC ACID DERIVATIVE; CANRENOATE POTASSIUM; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FIBRINOGEN RECEPTOR ANTAGONIST; INSULIN GLARGINE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SPIRONOLACTONE; TRIAMTERENE;

ADJUVANT THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FRANCE; HUMAN; HYPERKALEMIA; HYPERTENSION; NOTE; UNITED KINGDOM;

ALDOSTERONE ANTAGONISTS; CLINICAL TRIALS; DRUG COSTS; EUROPE; GREAT BRITAIN; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE;

EID: 33750377749     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002070     Document Type: Note

References (18)

1. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004; 217: 45-52.
2. Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spironolactone: Mechanisms of action. Endocrinology 1975; 97: 52-58.
3. Froment A, Milon H. Etude en double aveugle de l'adjonction de spironolactone au traitement antihy-pertenseur thiazidique. La frácequence de la gynécomastie aur cours des tratements prolongés. In: External Activity of Aldosterone and its Antagonists. Excerpta Medica: Paris, 1971, pp 64-69.
4. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825.
5. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19: 353-361.
6. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930.
7. Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426-433.
8. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
9. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-716.
10. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026.
11. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148-1155.
12. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990-996.
13. Burgess ED, Lacourciere Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003; 25: 2388-2404.
14. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
15. Prisant LM, Krum H, Roniker B, Krause SL, Fakouhi K, He W. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003; 43: 1203-1210.
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
17. Jessani S, Watson T, Cappuccio FP, Lip GY. Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines. J Hum Hypertens 2006; 20(9): 641-645.
18. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al., British Hypertension Society. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18(3): 139-185.